Naproxen/pregabalin- Xgene Pharmaceutical

Drug Profile

Naproxen/pregabalin- Xgene Pharmaceutical

Alternative Names: Naproxen/pregabalin; Pregabalin/naproxen; XG005

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xgene Pharmaceutical
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Antipyretics; Antirheumatics; Anxiolytics; Naphthaleneacetic acids; Neuroprotectants; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pain

Most Recent Events

  • 12 Oct 2017 Chemical structure information added
  • 21 Sep 2017 Xgene Pharmaceutical plans a phase I trial for Chronic pain in Australia (In volunteers) in September 2017 (ACTRN12617001330336p)
  • 05 Sep 2017 Preclinical trials in Pain in Australia (PO), before September 2017 (ACTRN12617001330336p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top